Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (50)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gillespie, S. H.
Right arrow Articles by Billington, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gillespie, S. H.
Right arrow Articles by Billington, O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 393-395
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

Activity of moxifloxacin against mycobacteria

S. H. Gillespie* and O. Billington

Department of Medical Microbiology, Royal Free and University Medical School, Rowland Hill St, London NW3 2PF, UK

Moxifloxacin is an 8-methoxyquinolone compound with activity against a wide range of bacteria. We tested its activity in comparison with four other quinolones and isoniazid against clinical isolates of mycobacteria. It proved to be the most active of the quinolones tested against Mycobacterium tuberculosis (MIC90 0.25 mg/L), Mycobacterium avium-intracellulare (MIC90 1.0 mg/L), Mycobacterium kansasii (MIC90 0.06 mg/L) and Mycobacterium fortuitum (MIC90 1 mg/L). These data indicate that moxifloxacin merits further study as an antimycobacterial agent.

* Corresponding author. Tel: +44-171-794-0500; Fax: +44-171-794-0433; E-mail: stepheng{at}rfhsm.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. Von Groll, A. Martin, P. Jureen, S. Hoffner, P. Vandamme, F. Portaels, J. C. Palomino, and P. A. da Silva
Fluoroquinolone Resistance in Mycobacterium tuberculosis and Mutations in gyrA and gyrB
Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4498 - 4500.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. van den Boogaard, G. S. Kibiki, E. R. Kisanga, M. J. Boeree, and R. E. Aarnoutse
New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development
Antimicrob. Agents Chemother., March 1, 2009; 53(3): 849 - 862.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. E. F. Pardillo, J. Burgos, T. T. Fajardo, E. D. Cruz, R. M. Abalos, R. M. D. Paredes, C. E. S. Andaya, and R. H. Gelber
Powerful Bactericidal Activity of Moxifloxacin in Human Leprosy
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3113 - 3117.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
P. D. Gaba, C. Haley, M. R. Griffin, E. Mitchel, J. Warkentin, E. Holt, P. Baggett, and T. R. Sterling
Increasing Outpatient Fluoroquinolone Exposure Before Tuberculosis Diagnosis and Impact on Culture-Negative Disease
Arch Intern Med, November 26, 2007; 167(21): 2317 - 2322.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Cynamon, M. R. Sklaney, and C. Shoen
Gatifloxacin in combination with rifampicin in a murine tuberculosis model
J. Antimicrob. Chemother., August 1, 2007; 60(2): 429 - 432.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J.-Y. Wang, L.-N. Lee, H.-C. Lai, S.-K. Wang, I-S. Jan, C.-J. Yu, P.-R. Hsueh, and P.-C. Yang
Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure
J. Antimicrob. Chemother., May 1, 2007; 59(5): 860 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. J. Burman, S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, et al.
Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis
Am. J. Respir. Crit. Care Med., August 1, 2006; 174(3): 331 - 338.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. H. Gillespie, R. D. Gosling, L. Uiso, N. E. Sam, E. G. Kanduma, and T. D. McHugh
Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis
J. Antimicrob. Chemother., December 1, 2005; 56(6): 1169 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
T.-S. Huang, C. M. Kunin, S. Shin-Jung Lee, Y.-S. Chen, H.-Z. Tu, and Y.-C. Liu
Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003
J. Antimicrob. Chemother., December 1, 2005; 56(6): 1058 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. Nuermberger, S. Tyagi, K. N. Williams, I. Rosenthal, W. R. Bishai, and J. H. Grosset
Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model
Am. J. Respir. Crit. Care Med., December 1, 2005; 172(11): 1452 - 1456.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. H. Gillespie, S. Basu, A. L. Dickens, D. M. O'Sullivan, and T. D. McHugh
Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates
J. Antimicrob. Chemother., August 1, 2005; 56(2): 344 - 348.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Guna, C. Munoz, V. Dominguez, A. Garcia-Garcia, J. Galvez, J.-V. de Julian-Ortiz, and R. Borras
In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii
J. Antimicrob. Chemother., June 1, 2005; 55(6): 950 - 953.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. Alcaide, L. Calatayud, M. Santin, and R. Martin
Comparative In Vitro Activities of Linezolid, Telithromycin, Clarithromycin, Levofloxacin, Moxifloxacin, and Four Conventional Antimycobacterial Drugs against Mycobacterium kansasii
Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4562 - 4565.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. L. Nuermberger, T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R. J. O'Brien, A. A. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset
Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis
Am. J. Respir. Crit. Care Med., November 15, 2004; 170(10): 1131 - 1134.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. Di Perri and S. Bonora
Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?
J. Antimicrob. Chemother., September 1, 2004; 54(3): 593 - 602.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. W. R. Pletz, A. De Roux, A. Roth, K.-H. Neumann, H. Mauch, and H. Lode
Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study
Antimicrob. Agents Chemother., March 1, 2004; 48(3): 780 - 782.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. F. B. Cheng, W. W. Yew, E. W. C. Chan, M. L. Chin, M. M. M. Hui, and R. C. Y. Chan
Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates
Antimicrob. Agents Chemother., February 1, 2004; 48(2): 596 - 601.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Garcia-Garcia, J. Galvez, J.-V. de Julian-Ortiz, R. Garcia-Domenech, C. Munoz, R. Guna, and R. Borras
New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method
J. Antimicrob. Chemother., January 1, 2004; 53(1): 65 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. D. Gosling, L. O. Uiso, N. E. Sam, E. Bongard, E. G. Kanduma, M. Nyindo, R. W. Morris, and S. H. Gillespie
The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis
Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1342 - 1345.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
U. H. Manjunatha, M. Dalal, M. Chatterji, D. R. Radha, S. S. Visweswariah, and V. Nagaraja
Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase
Nucleic Acids Res., May 15, 2002; 30(10): 2144 - 2153.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. J. Alvirez-Freites, J. L. Carter, and M. H. Cynamon
In Vitro and In Vivo Activities of Gatifloxacin against Mycobacterium tuberculosis
Antimicrob. Agents Chemother., April 1, 2002; 46(4): 1022 - 1025.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. J. V. Piddock and V. Ricci
Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv
J. Antimicrob. Chemother., December 1, 2001; 48(6): 787 - 791.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
S. H. GILLESPIE, I. MORRISSEY, and D. EVERETT
A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model
J. Med. Microbiol., June 1, 2001; 50(6): 565 - 570.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.